L-778123

L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively[1][2].

Product Specifications

CAS Number

[183499-57-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Farnesyl Transferase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/l-778123.html

Purity

99.92

Solubility

1 M HCl : ≥ 100 mg/mL|DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCl)

Smiles

N#CC1=CC=C(CN2C(CN3CC(N(C4=CC=CC(Cl)=C4)CC3)=O)=CN=C2)C=C1

Molecular Formula

C22H20ClN5O

Molecular Weight

405.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Lobell RB, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther. 2002 Jul;1 (9) :747-758.|[2]Ghasemi S, et al. Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines. Adv Pharm Bull. 2013;3 (1) :73-77.|[3]Fredrick O. Onono, et al. The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity. Blood (2008) ; 112 (11) : 2627.|[4]Si MS, et al. Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123. Invest New Drugs. 2005 Jan;23 (1) :21-9.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

ACS Nano. 2025 Aug 12;19 (31) :28644-28659.|bioRxiv. 2025 Jul 29.|bioRxiv. 2023 Feb 8:2023.02.07.527548.|Cell. 2025 Nov 24:S0092-8674 (25) 01244-9.|Immunity. 2024 May 14;57 (5) :1056-1070.e5.